# The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

> **NCT07152340** · PHASE4 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Thyroid Associated Ophthalmopathies

## Interventions

- **DRUG:** IBI311
- **DRUG:** Glucocorticoids

## Key facts

- **NCT ID:** NCT07152340
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-05-01
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152340, "The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07152340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*